Assembly Biosciences. has been granted a patent for 5-membered heteroaryl carboxamide compounds that disrupt HBV core protein assembly. The patent includes pharmaceutical compositions and methods for treating Hepatitis B infection, along with a specific method for synthesizing one of the compounds. GlobalData’s report on Assembly Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Assembly Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Assembly Biosciences's grant share as of July 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Heteroaryl carboxamide compounds for treating hepatitis b
The granted patent US12030869B2 outlines a method for synthesizing a specific compound referred to as compound (VI-5). The claims detail various aspects of the synthesis process, emphasizing the structural characteristics of the compound. Claim 1 establishes the foundational method for the synthesis, while subsequent claims refine the parameters by specifying the substituents on the aromatic group (Ar) and the alkyl group (R). Notably, claim 2 specifies that Ar is a phenyl group that is substituted with both chloro and fluoro groups, indicating a focus on halogenated derivatives.
Further, claim 4 narrows the synthesis method by defining R as a methyl group, which suggests that the compound (VI-5) may possess specific properties or functionalities associated with this substitution. The claims collectively highlight the innovative aspects of the synthesis method, which may have implications for the development of new chemical entities or materials. The patent provides a structured approach to creating compound (VI-5), potentially contributing to advancements in various applications within the chemical and pharmaceutical industries.
To know more about GlobalData’s detailed insights on Assembly Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.